The new HealthVerity: View from the Curisium CEO
Last week, HealthVerity announced its acquisition of Curisium, an innovator in cloud-based drug...
Last week, HealthVerity announced its acquisition of Curisium, an innovator in cloud-based drug...
This week’s webinar, VBA 2.0 Building and accelerating VBA for the next era, offered a deeper look...
Value-based agreements unite pharma companies and payers with a mutually beneficial payment model,...
Throughout the past quarter, we’ve announced major collaborations, built on existing partnerships...
The COVID-19 outbreak has created an unprecedented need for real-time data. As the global pandemic...
The coronavirus pandemic continues to be a disruptive force for patients and physicians across the...
Healthcare has the lowest digital ad spend among major industries today. Privacy protection laws...
Few areas of medicine have captured public interest over the past two years quite like glucagon-like peptide-1 (GLP-1) receptor agonists. Originally developed to improve glycemic control in type 2 diabetes, drugs like semaglutide (Ozempic/Wegovy) and...